BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19627396)

  • 1. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.
    Leali D; Bianchi R; Bugatti A; Nicoli S; Mitola S; Ragona L; Tomaselli S; Gallo G; Catello S; Rivieccio V; Zetta L; Presta M
    J Cell Mol Med; 2010 Aug; 14(8):2109-21. PubMed ID: 19627396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.
    Rusnati M; Camozzi M; Moroni E; Bottazzi B; Peri G; Indraccolo S; Amadori A; Mantovani A; Presta M
    Blood; 2004 Jul; 104(1):92-9. PubMed ID: 15031207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.
    Leali D; Inforzato A; Ronca R; Bianchi R; Belleri M; Coltrini D; Di Salle E; Sironi M; Norata GD; Bottazzi B; Garlanda C; Day AJ; Presta M
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):696-703. PubMed ID: 22267482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers.
    Giacomini A; Matarazzo S; Pagano K; Ragona L; Rezzola S; Corsini M; Di Salle E; Presta M; Ronca R
    Oncotarget; 2015 May; 6(15):13790-802. PubMed ID: 25912421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.
    Ronca R; Di Salle E; Giacomini A; Leali D; Alessi P; Coltrini D; Ravelli C; Matarazzo S; Ribatti D; Vermi W; Presta M
    Mol Cancer Ther; 2013 Dec; 12(12):2760-71. PubMed ID: 24130051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3.
    Camozzi M; Rusnati M; Bugatti A; Bottazzi B; Mantovani A; Bastone A; Inforzato A; Vincenti S; Bracci L; Mastroianni D; Presta M
    J Biol Chem; 2006 Aug; 281(32):22605-13. PubMed ID: 16769728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
    Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
    J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.
    Leali D; Alessi P; Coltrini D; Rusnati M; Zetta L; Presta M
    Curr Pharm Des; 2009; 15(30):3577-89. PubMed ID: 19860702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.
    Leali D; Alessi P; Coltrini D; Ronca R; Corsini M; Nardo G; Indraccolo S; Presta M
    Mol Cancer Ther; 2011 Sep; 10(9):1600-10. PubMed ID: 21764903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
    Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2.
    Presta M; Foglio E; Churruca Schuind A; Ronca R
    Front Immunol; 2018; 9():2327. PubMed ID: 30349543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors.
    Nawaz IM; Chiodelli P; Rezzola S; Paganini G; Corsini M; Lodola A; Di Ianni A; Mor M; Presta M
    Angiogenesis; 2018 Feb; 21(1):47-59. PubMed ID: 29030736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2.
    Inforzato A; Baldock C; Jowitt TA; Holmes DF; Lindstedt R; Marcellini M; Rivieccio V; Briggs DC; Kadler KE; Verdoliva A; Bottazzi B; Mantovani A; Salvatori G; Day AJ
    J Biol Chem; 2010 Jun; 285(23):17681-92. PubMed ID: 20363749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells.
    O'Neill CL; Guduric-Fuchs J; Chambers SE; O'Doherty M; Bottazzi B; Stitt AW; Medina RJ
    Cardiovasc Res; 2016 Dec; 112(3):677-688. PubMed ID: 27659714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.
    Camozzi M; Zacchigna S; Rusnati M; Coltrini D; Ramirez-Correa G; Bottazzi B; Mantovani A; Giacca M; Presta M
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1837-42. PubMed ID: 16020751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.
    Leali D; Belleri M; Urbinati C; Coltrini D; Oreste P; Zoppetti G; Ribatti D; Rusnati M; Presta M
    J Biol Chem; 2001 Oct; 276(41):37900-8. PubMed ID: 11473122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caveolin-1 orchestrates fibroblast growth factor 2 signaling control of angiogenesis in placental artery endothelial cell caveolae.
    Feng L; Liao WX; Luo Q; Zhang HH; Wang W; Zheng J; Chen DB
    J Cell Physiol; 2012 Jun; 227(6):2480-91. PubMed ID: 21830216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component.
    Bottazzi B; Vouret-Craviari V; Bastone A; De Gioia L; Matteucci C; Peri G; Spreafico F; Pausa M; D'Ettorre C; Gianazza E; Tagliabue A; Salmona M; Tedesco F; Introna M; Mantovani A
    J Biol Chem; 1997 Dec; 272(52):32817-23. PubMed ID: 9407058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.